Sectors & IndustriesHealthcareDiagnostics & Research

Best Diagnostics & Research Stocks to Buy Now (2022)

Top diagnostics & research stocks in 2022 ranked by overall Zen Score. See the best diagnostics & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

According to Zen Score, the 3 best diagnostics & research stocks to buy right now are:

QUIDEL (NASDAQ:QDEL) is the top diagnostics & research stock with a Zen Score of 57, which is 24 points higher than the diagnostics & research industry average of 33. It passed 18 out of 33 due diligence checks and has strong fundamentals. QUIDEL has seen its stock lose -12.94% over the past year, overperforming other diagnostics & research stocks by 9 percentage points.

QUIDEL has an average 1 year price target of $145.00, an upside of 44.42% from QUIDEL's current stock price of $100.40.

QUIDEL stock has a consensus Hold recommendation according to Wall Street analysts. Of the 3 analysts covering QUIDEL, 33.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 33.33% have issued a Strong Sell.

-DIAGNOSTICS (NASDAQ:CODX) is the second best diagnostics & research stock with a Zen Score of 53, which is 20 points higher than the diagnostics & research industry average of 33. It passed 17 out of 33 due diligence checks and has strong fundamentals. -DIAGNOSTICS has seen its stock lose -43.46% over the past year, underperforming other diagnostics & research stocks by -22 percentage points.

-DIAGNOSTICS has an average 1 year price target of $12.00, an upside of 164.32% from -DIAGNOSTICS's current stock price of $4.54.

-DIAGNOSTICS stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering -DIAGNOSTICS, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

SYNEOS HEALTH (NASDAQ:SYNH) is the third best diagnostics & research stock with a Zen Score of 52, which is 19 points higher than the diagnostics & research industry average of 33. It passed 17 out of 33 due diligence checks and has strong fundamentals. SYNEOS HEALTH has seen its stock lose -20.46% over the past year, overperforming other diagnostics & research stocks by 1 percentage points.

SYNEOS HEALTH has an average 1 year price target of $98.86, an upside of 40.1% from SYNEOS HEALTH's current stock price of $70.56.

SYNEOS HEALTH stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 8 analysts covering SYNEOS HEALTH, 62.5% have issued a Strong Buy rating, 12.5% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 9 diagnostics & research stocks that have issued dividends in the past year, the 3 diagnostics & research stocks with the highest dividend yields are:

KONINKLIJKE PHILIPS NV (NYSE:PHG) has an annual dividend yield of 3.82%, which is 3 percentage points higher than the diagnostics & research industry average of 1.1%. KONINKLIJKE PHILIPS NV's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. KONINKLIJKE PHILIPS NV's dividend has not shown consistent growth over the last 10 years.

KONINKLIJKE PHILIPS NV's dividend payout ratio of 24.8% indicates that its dividend yield is sustainable for the long-term.

NATIONAL RESEARCH (NASDAQ:NRC) has an annual dividend yield of 1.82%, which is 1 percentage points higher than the diagnostics & research industry average of 1.1%. NATIONAL RESEARCH's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. NATIONAL RESEARCH's dividend has shown consistent growth over the last 10 years.

NATIONAL RESEARCH's dividend payout ratio of 41.4% indicates that its dividend yield is sustainable for the long-term.

QUEST DIAGNOSTICS (NYSE:DGX) has an annual dividend yield of 1.8%, which is 1 percentage points higher than the diagnostics & research industry average of 1.1%. QUEST DIAGNOSTICS's dividend payout is stable, having never dropped by more than 10% in the last 10 years. QUEST DIAGNOSTICS's dividend has shown consistent growth over the last 10 years.

QUEST DIAGNOSTICS's dividend payout ratio of 16.4% indicates that its dividend yield is sustainable for the long-term.

Diagnostics & research stocks were down -2.05% in the last day, and down -2.25% over the last week. DEXCOM was the among the top losers in the diagnostics & research industry, dropping -11.05% yesterday.

DexCom shares are trading lower following a Bloomberg report suggesting the company is in talks to acquire Insulet.

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostics & research stocks right now are:

-DIAGNOSTICS (NASDAQ:CODX) is the most undervalued diagnostics & research stock based on WallStreetZen's Valuation Score. -DIAGNOSTICS has a valuation score of 71, which is 38 points higher than the diagnostics & research industry average of 33. It passed 5 out of 7 valuation due diligence checks.

-DIAGNOSTICS's stock has dropped -43.46% in the past year. It has underperformed other stocks in the diagnostics & research industry by -22 percentage points.

QUIDEL (NASDAQ:QDEL) is the second most undervalued diagnostics & research stock based on WallStreetZen's Valuation Score. QUIDEL has a valuation score of 71, which is 38 points higher than the diagnostics & research industry average of 33. It passed 5 out of 7 valuation due diligence checks.

QUIDEL's stock has dropped -12.94% in the past year. It has overperformed other stocks in the diagnostics & research industry by 9 percentage points.

MERIDIAN BIOSCIENCE (NASDAQ:VIVO) is the third most undervalued diagnostics & research stock based on WallStreetZen's Valuation Score. MERIDIAN BIOSCIENCE has a valuation score of 71, which is 38 points higher than the diagnostics & research industry average of 33. It passed 5 out of 7 valuation due diligence checks.

MERIDIAN BIOSCIENCE's stock has gained 30.11% in the past year. It has overperformed other stocks in the diagnostics & research industry by 52 percentage points.